SOUTH SAN FRANCISCO, Calif., Aug. 31, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that management will present at the following upcoming investor relations events.

• JP Morgan CEO Series
  Fireside Chat hosted by Analyst Anupam Rama
  Tuesday, September 8, 2020 at 12:00pm ET

• Citi 15^th Annual BioPharma Conference
  Company Panel: Precision Targeted Drugs in Oncology hosted by Analyst Mohit Bansal
  Wednesday, September 9^th at 11:40am ET

• RW Baird Global Health Care Conference
  Fireside Chat hosted by Analyst Madhu Kumar
  Thursday, September 10^th at 3:45pm ET

• H.C. Wainwright 22^nd Annual Global Investment Conference
  Company Presentation
  Monday, September 14^th at 11:30am ET

IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies IDEAYA is developing.  IDEAYA is applying these capabilities across multiple classes of precision medicine, including synthetic lethality – which represents an emerging class of precision medicine targets. 

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Quarterly Report on Form 10-Q filed on August 12, 2020 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.